In San Diego, California on May 21, 2026, First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a biotech company in the clinical stage, revealed plans for its executives, including President and CEO Daniel Faga, to take part in several upcoming investor conferences. The company is focused on developing antibody therapeutics that target immune pathways linked to autoimmune and inflammatory conditions.